EUVIMEDEUVIMED entdecken
Crossref

Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation

Lorenzo Da Dalt, Fabrizia Bonacina

European Atherosclerosis Journal · 2022

DOI: 10.56095/eaj.v1i2.13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Atherosclerosis Journal, 2022. Verfasst von Lorenzo Da Dalt und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) protease is a 692 amino acid glycoprotein which belongs to the proprotein convertase family. PCSK9 binds several receptors of the LDL family, including VLDLR, LRP1 but also with CD36, driving their lysosomal degradation. From the beginning of the 21st century a growing body of interest raised around the opportunity to pharmacologically inhibit PCSK9, and most recently, monoclonal antibodies have been successfully tested for the treatment of severe/genetic forms of dyslipidemia. Despite the majority of circulating PCSK9 being produced by the liver, other organs come into play contributing to its production, such as the heart, the pancreas, and the brain. Nonetheless, extrahepatic PCSK9 may exert a local/paracrine and or autocrine metabolic impact in the homeostatic regulation of cholesterol metabolism, suggesting that, opposite to the liver, in other tissue PCSK9 deficiency or inhibition could contribute to the development of specific organ and tissues dysfunctionalities.

Zitieren

APA

Dalt, L. D., & Bonacina, F. (2022). Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. European Atherosclerosis Journal. https://doi.org/10.56095/eaj.v1i2.13

Vancouver

Dalt LD, Bonacina F. Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. European Atherosclerosis Journal. 2022. doi:10.56095/eaj.v1i2.13

BibTeX
@article{Dalt2022,
  author = {Dalt, Lorenzo Da and Bonacina, Fabrizia},
  title = {Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation},
  journal = {European Atherosclerosis Journal},
  year = {2022},
  doi = {10.56095/eaj.v1i2.13}
}
Kostenlos starten →